secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0000950170-24-036399
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon reports Q4 2023 net loss $27.9M; cash $259.7M; Phase 3 GBS data Q2 2024
-------------------------------------------------------------------------------

- Net loss for FY2023 $134.2M vs $141.9M in prior year; R&D spend $113.8M.
- Cash and short-term investments $259.7M as of Dec 31, 2023; runway into mid-2026.
- Phase 3 ANX005 GBS topline data expected Q2 2024; BLA submission supported by RWE from IGOS.
- Phase 3 ANX007 GA ARCHER II trial (sham-controlled) to initiate mid-2024; ARROW head-to-head vs SYFOVRE planned H2 2024.
- Completed $125M financing in December 2023 extending operating runway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000095017024036399/0000950170-24-036399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000095017024036399/annx-20240326.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer